BGES Bio Bridge Science Inc (CE)

Bio-Bridge Science, Inc. (OTCBB:BGES) announced today its participation in a study, entitled Private Sector Development in Developing Countries: Targeting Local Health Needs through Health Technology, which explores how small to medium enterprises can address local health needs in Innovating Developing Countries (IDCs) such as China, India, Brazil and South Africa. Two members of the research team, Dr. Sarah E. Frew and Dr. Peter A. Singer, visited Bio-Bridge Science's soon to be finished GMP lab facility and met with senior management on May 15, 2006 in Beijing. As part of the study, Bio-Bridge Science, Inc. will participate in exploring ways that the domestic private sector can contribute to the development of health technologies targeted to address local health needs. The mission of Bio-Bridge Science, Inc. is to develop and produce new vaccines and drugs to treat human diseases and improve human health. "We are honored to be selected to participate in this study," said Dr. Liang Qiao, Chief Executive Officer of Bio-Bridge. "The exposure among many of the key thought and opinion leaders in these countries will raise our profile in these key markets. As a Company that has focused on developing cost-effective vaccines for large unmet medical needs in countries such as China, we believe that we are uniquely qualified to offer solutions to these challenges." About Bio-Bridge Science: Bio-Bridge Science is a biotechnology firm focused on the development of vaccines with broad therapeutic and preventive applications. Through its wholly owned subsidiary in Beijing, Bio-Bridge is developing a promising new HIV Vaccine that is expected to enter clinical trials this year in China. The vaccine, based on exclusive technology co-developed by CEO Liang Qiao, an associate professor at Loyola University Chicago's Strich School of Medicine, targets infection in mucosal tissues, the first type of tissue attacked by HIV. The Chinese government, mindful of the rapid expansion of AIDS in China has, through the "Green Mile Policy", acted to expedite the approval of domestically produced HIV Vaccines and has dramatically increased its spending on AIDS-related research. In accordance with this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine to market as early as late 2008, far in advance of many other HIV Vaccines currently in development. Bio-Bridge is currently constructing a new $3 million state-of-the-art GMP research and manufacturing facility in Beijing, which is expected to be completed by mid-year. The facility will also be used to develop vaccines against cervical cancer and colon cancer under the same technology platform as the HIV vaccine.